Skip to content

Clinical trials

Lymphoma, T-Cell, Cutaneous trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, T-Cell, Cutaneous Country / region: China Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20181
20191
20222
20232
20243
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting7
Unknown status3
Completed2
Not yet recruiting2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking Union Medical College Hospital3
Peking University First Hospital3
Beijing GoBroad Hospital2
BeiGene1
Chengdu Zenitar Biomedical Technology Co., Ltd1
Institute of Hematology & Blood Diseases Hospital, China1
Jiangsu Simcere Biologics Co., Ltd1
Kyowa Kirin China Pharmaceutical Co., Ltd.1
Shanghai Jiao Tong University School of Medicine1
Tianjin Medical University Cancer Institute and Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, T-Cell, Cutaneous15
Lymphoma, T-Cell4
Lymphoma, T-Cell, Peripheral3
Recurrence3
Lymphoma, Non-Hodgkin2
Mycosis Fungoides2
Sezary Syndrome2
Immunoblastic Lymphadenopathy1
Leukemia, Large Granular Lymphocytic1
Lymphoma, Extranodal NK-T-Cell1

Trials

Showing 51 to 15 of 15. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.